Sir, In recent years, the emergence and dissemination of extendedspectrum b-lactamases (ESBLs) among clinical Escherichia coli isolates in human medicine has become a cause of great concern, as this mechanism of resistance is implicated in treatment failure. 1 Previous reports have demonstrated the presence of ESBLproducing E. coli in faecal samples of wild animals in Portugal. 2, 3 The occurrence of ESBL-producing E. coli in wild animals has potential implications for veterinary medicine and human public health as these animals may serve as a source for the transmission of resistant organisms to other animals or even humans.
One hundred and fifty-four thrushes were captured by hunting associations in the north of Portugal between November 2009 and February 2010, during the thrush hunting season. This hunting is supervised by the Agriculture, Rural Development and No ESBL producers were detected in the 154 thrush faecal samples, contrary to our initial expectations, in view of the marked presence of ESBL-producing E. coli in other wild birds, particularly buzzards, 3 and other animals such as wild boars. 2 The current absence of ESBL-producing E. coli in thrushes can possibly be explained by the feeding habits of this bird, where the diet is based mainly on invertebrates and soft fruit and berries. 4 In addition, the absence of ESBL-producing E. coli may also be related to the fact that thrushes are migratory birds, leaving the Baltic region in the autumn and returning in early spring, 5 having a relative short stay in Portugal. Previous studies have confirmed that in most northern European countries, the prevalence of ESBL producers in human clinical medicine is relatively low and have not reported isolates from animals in contrast to southern European countries. Sir, We have recently demonstrated that aminosterol derivatives (ASDs) possess an interesting in vitro antibacterial activity against multidrug-resistant bacteria recovered from cystic fibrosis (CF) patients. 1 However, mould infections are also a serious threat for CF patients. 2 Indeed, the fragile pulmonary environment of these patients facilitates the development of bacterial and fungal infections. 2 Repeated bacterial infections, intensive antibiotic therapy and lung transplantation are considered as risk factors for airway infection and/or colonization by moulds in CF patients. 2 Major problems are related to Aspergillus spp. and Scedosporium spp. that may cause chronic disorders such as asthma, bronchitis and aspergilloma.
2 Amphotericin B, caspofungin and azoles are currently used in the management of fungal infections. However, in addition to acquired resistance resulting from antifungal treatment pressure as noted for Aspergillus spp., intrinsic resistance to available antifungals reported in some fungi such as Fusarium, Rhizopus, Rhizomucor and Scedosporium spp. represents a major issue, highlighting the need to develop new antifungal compounds. 2, 3 ASDs have been evaluated only against reference fungal strains. 4 We evaluated herein for the first time the in vitro antifungal activity of squalamine and one of our compounds (ASD 1; the chemical structure is available in Alhanout et al.
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) possessing an in vitro antibacterial effect, 1 against a panel of clinical mould isolates recovered from sputa of CF patients. All tested isolates were identified at the species level using partial internal transcribed spacer PCR amplification, and the sequencing procedure and sequences have been
